On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

The European stock markets closed higher in Thursday trading as The Stoxx Europe rose 1.08%, Germany's DAX climbed 1.26%, the FTSE in London was up 0.51%, France's CAC advanced 1.32%, and the Swiss ...

Blenrep (belantamab mafodotin). Since Blenrep made its debut last year, Bristol-Myers Squibb and bluebird bio have also claimed approval for their BCMA-targeted CAR-T therapy Abecma (idecabtagene ...